Cargando…

Biphenyl Ether Analogs Containing Pomalidomide as Small-Molecule Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction

New biphenyl-based chimeric compounds containing pomalidomide were developed and evaluated for their activity to inhibit and degrade the programmed cell death-1/programmed cell death- ligand 1 (PD-1/PD-L1) complex. Most of the compounds displayed excellent inhibitory activity against PD-1/PD-L1, as...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shaabani, Shabnam, Gadina, Louis, Surmiak, Ewa, Wang, Zefeng, Zhang, Bidong, Butera, Roberto, Zarganes-Tzitzikas, Tryfon, Rodriguez, Ismael, Kocik-Krol, Justyna, Magiera-Mularz, Katarzyna, Skalniak, Lukasz, Dömling, Alexander, Holak, Tad A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9181982/ https://www.ncbi.nlm.nih.gov/pubmed/35684392 http://dx.doi.org/10.3390/molecules27113454

Ejemplares similares

Terphenyl-Based Small-Molecule Inhibitors of Programmed Cell Death-1/Programmed Death-Ligand 1 Protein–Protein Interaction
por: Muszak, Damian, et al.
Publicado: (2021)

PD-L1 Inhibitors: Different Classes, Activities, and Mechanisms of Action
por: Surmiak, Ewa, et al.
Publicado: (2021)

Design, Synthesis, and Biological Evaluation of 2-Hydroxy-4-phenylthiophene-3-carbonitrile as PD-L1 Antagonist and Its Comparison to Available Small Molecular PD-L1 Inhibitors
por: Ważyńska, Marta A., et al.
Publicado: (2023)

Design of indole- and MCR-based macrocycles as p53-MDM2 antagonists
por: Neochoritis, Constantinos G, et al.
Publicado: (2019)

Computer- and NMR-Aided Design of Small-Molecule Inhibitors of the Hub1 Protein
por: Reyes Romero, Atilio, et al.
Publicado: (2022)

Helping the Released Guardian: Drug Combinations for Supporting the Anticancer Activity of HDM2 (MDM2) Antagonists
por: Kocik, Justyna, et al.
Publicado: (2019)

CA-170 – A Potent Small-Molecule PD-L1 Inhibitor or Not?
por: Musielak, Bogdan, et al.
Publicado: (2019)

Atorvastatin (Lipitor) by MCR
por: Zarganes-Tzitzikas, Tryfon, et al.
Publicado: (2019)

Multicomponent reaction–derived covalent inhibitor space
por: Sutanto, Fandi, et al.
Publicado: (2021)

Structural and biological characterization of pAC65, a macrocyclic peptide that blocks PD-L1 with equivalent potency to the FDA-approved antibodies
por: Rodriguez, Ismael, et al.
Publicado: (2023)

MCR Scaffolds Get Hotter with (18)F-Labeling
por: Zarganes-Tzitzikas, Tryfon, et al.
Publicado: (2019)

Late-Stage Copper-Catalyzed Radiofluorination of an Arylboronic Ester Derivative of Atorvastatin
por: S. Clemente, Gonçalo, et al.
Publicado: (2019)

Nanoscale, automated, high throughput synthesis and screening for the accelerated discovery of protein modifiers
por: Gao, Kai, et al.
Publicado: (2021)

Design, Synthesis, and Biological Evaluation of Imidazopyridines as PD-1/PD-L1 Antagonists
por: Butera, Roberto, et al.
Publicado: (2021)

Human and mouse PD-L1: similar molecular structure, but different druggability profiles
por: Magiera-Mularz, Katarzyna, et al.
Publicado: (2020)

Multicomponent Reactions: “Kinderleicht”
por: Neochoritis, Constantinos G., et al.
Publicado: (2020)

Di-bromo-Based Small-Molecule Inhibitors of the PD-1/PD-L1 Immune Checkpoint
por: Konieczny, Magdalena, et al.
Publicado: (2020)

Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1)
por: Zak, Krzysztof M., et al.
Publicado: (2016)

Application of Silver Nanoparticles in the Multicomponent Reaction Domain: A Combined Catalytic Reduction Methodology to Efficiently Access Potential Hypertension or Inflammation Inhibitors
por: Iordanidou, Domna, et al.
Publicado: (2018)

Synthesis of Highly Substituted Imidazole Uracil Containing Molecules via Ugi-4CR and Passerini-3CR
por: Madhavachary, Rudrakshula, et al.
Publicado: (2018)

Prolonged Idasanutlin (RG7388) Treatment Leads to the Generation of p53-Mutated Cells
por: Skalniak, Lukasz, et al.
Publicado: (2018)

Small-molecule inhibitors of PD-1/PD-L1 immune checkpoint alleviate the PD-L1-induced exhaustion of T-cells
por: Skalniak, Lukasz, et al.
Publicado: (2017)

[(18)F]Atorvastatin: synthesis of a potential molecular imaging tool for the assessment of statin-related mechanisms of action
por: Clemente, Gonçalo S., et al.
Publicado: (2020)

Competition NMR for Detection of Hit/Lead Inhibitors of Protein–Protein Interactions
por: Musielak, Bogdan, et al.
Publicado: (2020)

Exploring the Surface of the Ectodomain of the PD-L1 Immune Checkpoint with Small-Molecule Fragments
por: Kitel, Radoslaw, et al.
Publicado: (2022)

PROTACs– a game-changing technology
por: Konstantinidou, Markella, et al.
Publicado: (2019)

Supported Gold Nanoparticle-Catalyzed Selective Reduction of Multifunctional, Aromatic Nitro Precursors into Amines and Synthesis of 3,4-Dihydroquinoxalin-2-Ones
por: Iordanidou, Domna, et al.
Publicado: (2022)

Rapid approach to complex boronic acids
por: Neochoritis, Constantinos G., et al.
Publicado: (2019)

Development of the Inhibitors That Target the PD-1/PD-L1 Interaction—A Brief Look at Progress on Small Molecules, Peptides and Macrocycles
por: Guzik, Katarzyna, et al.
Publicado: (2019)

Lithocholic Acid Hydroxyamide Destabilizes Cyclin D1 and Induces G(0)/G(1) Arrest by Inhibiting Deubiquitinase USP2a
por: Magiera, Katarzyna, et al.
Publicado: (2017)

Programmed cell death
Publicado: (1994)

Programmed death ligand-1/programmed death-1 inhibition therapy and programmed death ligand-1 expression in urothelial bladder carcinoma
por: Yu, Wei-Bo, et al.
Publicado: (2019)

Inhibition of the NLRP3 inflammasome by HSP90 inhibitors
por: Nizami, Sohaib, et al.
Publicado: (2020)

Discovery and Development Strategies for SARS-CoV-2 NSP3 Macrodomain Inhibitors
por: Schuller, Marion, et al.
Publicado: (2023)

Cancer and programmed cell death
por: Croker, Ben, et al.
Publicado: (2003)

Programmed Cell Death in Cystinosis
por: Ames, Elizabeth G., et al.
Publicado: (2022)

Programmed cell death lives
por: Griffioen, Arjan W., et al.
Publicado: (2022)

Regulation of Neuroinflammation through Programed Death-1/Programed Death Ligand Signaling in Neurological Disorders
por: Zhao, Shangfeng, et al.
Publicado: (2014)

Soluble programmed cell death protein-1 and programmed cell death ligand-1 in sepsis
por: Banerjee, Debasree, et al.
Publicado: (2018)

Programmed cell death-1 and programmed cell death ligand-1 antibodies-induced dysthyroidism
por: Jaafar, Jaafar, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_8pq826sulds4nkgqlsntiv2fvv